Ronkyla Plus

Phase 1Small molecule

GGlonova Pharma Co., Ltd

Ronkyla Plus is one of 8 small molecule programs targeting Lipoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LipomaActive, not recruiting

LipomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Lipoma

#DrugCompanyPhaseTrials

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—2

Xiaflex

GGrupo Espanol de Tumores Neuroendocrinos

Phase 2

1 3

Kybella

AbbVie

Phase 1

2 4

AA4500

Endo Pharmaceuticals

Phase 2

1 5

Kybella

AbbVie

Phase 1

1 6

CBL-514

CCaliway Biopharmaceuticals Co., Ltd.

Phase 2

2 7

RZL-012

RRaziel Therapeutics Ltd.

Phase 2

1 8

Ronkyla Plus

GGlonova Pharma Co., Ltd

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Lipoma

NCT07237425

Clinical

Trials by Indication[1]

Lipoma1 trial

Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma

Recruiting·GGlonova Pharma Co., Ltd·Phase 1·NCT07237425·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ronkyla Plus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ronkyla Plus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ronkyla Plus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Glonova Pharma Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GGlonova Pharma Co., Ltd

Ronkyla Plus

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Lipoma1 trial

References

Drug Info

Quick Facts

Related News